ClinicalTrials.gg
CompletedNCT04279119MUSEUpdated Aug 3, 2022

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

A Phase 1 interventional study of ARQ-151- cream 0.3% in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 12 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
12th of 17
26 · median 46
Started
2020
with 2 others
Phase 1
Only one
of the 17
Registered
7th of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one is the 12th largest by enrollment, is one of 3 that started in 2020, is the only one in phase 1, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp).

The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants legally competent to sign and give or for adolescents assent with consent of a parent or legal guardian.
  2. Males and females ages 12 years and older (inclusive) at the time of consent/assent.
  3. Clinical diagnosis of psoriasis vulgaris of at least 3 months duration as determined by the Investigator or through subject interview. Stable disease for the past 4 weeks.
  4. Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas involving at least 10% of BSA in adolescents and at least 20% of BSA in adults (excluding the scalp).
  5. An Investigator Global Assessment of disease severity of at least Moderate ('3') at Baseline.
  6. Females of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the trial.
  7. Females of non-childbearing potential should be premenarchal, with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
  8. Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, 12-lead , serum chemistry labs, hematology values, and urinalysis.
  9. Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who cannot discontinue medication and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (Table 1).
  2. Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other light emitting diode (LED).
  3. Subjects currently taking lithium or antimalarial drugs.
  4. Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).
  5. Current diagnosis of non-plaque form of psoriasis (e.g., guttate, erythrodermic/exfoliative, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.
  6. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
  7. Known allergies to in ARQ-151 cream
  8. Subjects who cannot discontinue the use of systemic strong P 450 cytochrome inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, fluconazole, nefazodone, saquinavir, suboxone and telithromycin) for two weeks prior to the Baseline visit and during the study period.
  9. Subjects who cannot discontinue the use of systemic strong P 450 cytochrome inducers (e.g., efavirenz, nevirapine, , barbiturates (including phenobarbital), phenytoin, rifampin and carbamazepine) for two weeks prior to the Baseline visit and during the study period.
  10. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  11. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE4 inhibitors (apremilast) within the past 4 weeks.
  12. Known or suspected:

    • severe renal insufficiency or moderate to severe liver impairment ( B or C)
    • known infection
    • to component(s) of the products
    • history of severe depression, suicidal ideation, Baseline/Screening C-SSRS indicative of suicidal ideation, whether lifetime or recent/current
  13. Adult subjects with PHQ-8 ≥10 or adolescent subjects with modified PHQ-A ≥10 at Screening or Baseline visits.
  14. Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product.
  15. Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
  16. Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation. For adolescent subjects; parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language.
  17. Subjects who are family members of the clinical study site, clinical study staff, or Sponsor.
  18. Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  19. Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
  20. Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    ARQ-151 cream 0.3%

    Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks

    Drug: ARQ-151- cream 0.3%

Interventions

  • ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of roflumilast and its major N-oxide metabolite

    Maximum observed concentration of drug in plasma metabolite

    Time frame: 5 weeks

  2. Area under the plasma concentration-time curve until the last quantifiable timepoint (AUC) for roflumilast and its N-oxide metabolite

    The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in plasma.

    Time frame: 5 weeks

  3. Time of maximum concentration (Tmax) of roflumilast and its major N-oxide metabolite

    Tmax is the time that a drug achieves maximum concentration in plasma

    Time frame: 5 weeks

Secondary outcomes

  1. Subject incidence of adverse events

    Number of participants with adverse events during treatment will be assessed

    Time frame: 5 weeks

  2. Incidence of application site reactions

    Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed

    Time frame: 5 weeks

  3. Incidence of application site reactions

    Percentage of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed

    Time frame: 5 weeks

  4. The incidence of suicide ideation as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a tool used to assess suicide risk, the severity and immediacy of that risk. The C-SSRS is made up of ten categories and includes questions that require binary responses (yes/no) to indicate a presence or absence of the behavior and follow-up questions for any behavior that is endorsed (yes) to collect additional information.

    Time frame: 5 weeks

  5. The incidence of changes from baseline in the Patient Health Questionnaire (PHQ-8) Depression Scale

    The PHQ-8 is an instrument used for screening, diagnosing, monitoring and measuring the severity of depression in adults. The score for the PHQ-8 ranges from 0-24 with a higher score reflecting a higher severity category of depression.

    Time frame: 5 weeks

  6. The incidence of changes from baseline in the Patient Health Questionnaire for Adolescents (PHQ-A) Depression Scale

    The PHQ-A is an instrument used for screening, diagnosing, monitoring and measuring the severity of depression in adolescents. The score for the PHQ-A ranges from 0-24 with a higher score reflecting a higher severity category of depression.

    Time frame: 5 weeks

07

Study locations

12 sites
  • Arcutis Clinical Site 09
    Rogers, Arkansas 72758, United States
  • Arcutis Clinical Site 11
    Fountain Valley, California 92708, United States
  • Arcutis Clinical Site 07
    Coral Gables, Florida 33134, United States
  • Arcutis Clinical Site 03
    Doral, Florida 33122, United States
  • Arcutis Clinical Site 06
    Hialeah, Florida 33016, United States
  • Arcutis Clinical Site 12
    Miami, Florida 33144, United States
  • Arcutis Clinical Site 04
    Sanford, Florida 32771, United States
  • Arcutis Clinical Site 02
    Plainfield, Indiana 46168, United States
  • Arcutis Clinical Site 01
    Dublin, Ohio 43016, United States
  • Arcutis Clinical Site 10
    Arlington, Texas 76011, United States
  • Arcutis Clinical Site 05
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 08
    Richmond, Virginia 23226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Mar 2021, 12 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Feb 20, 2020
StartActual
Mar 10, 2020
Primary completionActual
Mar 25, 2021
CompletionActual
Mar 25, 2021
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04279119
Responsible party
Sponsor
First posted
Feb 20, 2020
Start date
Mar 10, 2020
Primary completion
Mar 25, 2021
Completion
Mar 25, 2021
Last update
Aug 3, 2022

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion